Modalités de préparation, cryopréservation, décongélation des cellules souches hématopoïétiques et précautions pour infusion au patient: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Modalités de préparation, cryopréservation, décongélation des cellules souches hématopoïétiques et précautions pour infusion au patient-recommandations de la SFGM-TC.pdf
[en] To date, despite an existing regulatory framework and standards, there are no true technical recommendations. A survey of 23 cell processing facilities (France, Belgium and Switzerland) has allowed to overview current practices according to cellular products specifications upon arrival at the facility, with modalities for their preparation prior to cryopreservation, storage, thawing and finally for infusion to patient. Data analysis shows great variability of collected volumes and cell concentrations in cellular products. Despite homogeneous practices for handling cells at the facility, methods vary between centers, especially for the choice of cryoprotective solutions and thawing methods. During the workshop, practices have been discussed and summarized to write of recommendations about the following topics: processing and cryopreservation, thawing, bedside precautions (for infusion). This work identifies some improvements in terms of collection, choice of wash solution of thawed cells and validation of the conditions of carriage.
Disciplines :
Hematology
Author, co-author :
Boulanger, Florence
Decot, Véronique
Bulliard, Geneviève
Calmels, Boris
Giraud, Christine
Lacassagne, Marie Noelle
Magnani, Alessandra
Pouthier, Fabienne
Thibert, Jean Baptiste
Tirefort, Yorkanda
Yakoub-Agha, Ibrahim
BAUDOUX, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
Language :
French
Title :
Modalités de préparation, cryopréservation, décongélation des cellules souches hématopoïétiques et précautions pour infusion au patient: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Alternative titles :
[en] Modalities for preparation, cryopreservation, thawing of hematopoietic stem cells and precautions for infusion to patient: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
[1] Akkök, C.A., Liseth, K., Melve, G.K., Ersvaer, E., Hervig, T., Bruserud, Ø., Is there a scientific basis for a recommended standardization of collection and cryopreservation of peripheral blood stem cell grafts?. Cytotherapy 13:8 (2011), 1013–1024, 10.3109/14653249.2011.574117 [Epub 2011 Apr 20. Review. PMID: 21504376].
[2] Fleming, K.K., Cryopreservation of hematopoietic and non-hematopoietic stem cells Transfusion and Apheresis. Science, 34, 2006.
[3] Sauer-Heilbronn, A., Patient care during infusion of hematopoietic progenitor cells. Transfusion, 2004.
[4] Martin-Henao, G.A., Adverse reactions during transfusion of thawed hematopoietic progenitor cells from apheresis are closely related to the number of granulocyte cells in the leukapheresis product. 2010, Vox sanguinis.
[5] Practical handbook of cell therapy cryopreservation. 2015, AABB.
[6] Clapisson, G., Cryopreservation with Hydroxyethylstarch (HES)+Dimethylsulfoxide (DMSO) gives better results than DMSO alone. Bull Cancer, 2004.
[7] Abbruzzese, L., A new freezing and storage procedure improves safety and viability of haematopoietic stem cells and neutrophil engraftment: a single institution experience. 2010, Vox sanguinis.
[8] Michael, A., Cox “Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide”. Cell Tissue Bank, 2012.
[9] Cordoba, R., The occurrence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product. BMT, 2007.
[10] Calmels, B., Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion, 2007.
[11] Paul Schlegel, Transient loss of consciousness in pediatric recipients of dimethylsulfoxide (DMSO)-cryopreserved peripheral blood stem cells independent of morphine co-medication. Haematologyca, 2009.
[12] Milone, G., Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age. Cytotherapie Vol, 2007.
[13] Bernal, T., Serious adverse events during hematopoietic stem cells infusion are determined by the number of infused granulocytes. EBMT, 2008, 457.
[14] Lemarie, C., Clinical experience with the delivery of thawed and washed autologous blood cell, with an automated closed fluid management device: cytomate. Transfusion, 2005.